The PPARs: From Orphan Receptors to Drug Discovery
The DOI matches its Crossref record; 215 of the 216 references it cites were found in a registry or an index.
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTThe PPARs: From Orphan Receptors to Drug Discovery†Timothy M. Willson, Peter J. Brown, Daniel D. Sternbach, and Brad R. HenkeView Author Information Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709 Cite this: J. Med. Chem. 2000, 43, 4, 527–550Publication Date (Web):February 24, 2000Publication History Received8 November 1999Published online24 February 2000Published inissue 1 February 2000https://pubs.acs.org/doi/10.1021/jm990554ghttps://doi.org/10.1021/jm990554greview-articleACS PublicationsCopyright © 2000 American Chemical SocietyRequest reuse permissionsArticle Views6740Altmetric-Citations1452LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Agonists,Ligands,Lipids,Receptors,Rodent models Get e-Alerts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pemafibrate is an extremely selective PPARα agonist (subtype selectivity > 5000-fold for PPARγ and > 11,000-fold for PPARδ, respectively) [49, 50].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
In the citing paper
“The PPARα activation by pemafibrate was > 2500 times stronger than fenofibric acid, the active form of fenofibrate.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
Citations
Cites
Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale
DeRisi, J. L., Iyer, V. R., & Brown, P. O. (1997) · Science · doi:10.1126/science.278.5338.680 · Cited by 4,456
Self-citationA Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis
Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., & Spiegelman, B. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81410-5 · Cited by 3,864
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Self-citationActivation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994) · Genes & Development · doi:10.1101/gad.8.10.1224 · Cited by 2,181
Research works printed but not linked: 124
- Lichtenstein A. H., 1998, Nutr. Rev., 56, S28
- Harris M. I., 1998, Diabetes Care, 21, 524
- Howard B. V., 1995, Int. Congr. Ser.
- Barzilai N., 1999, J. Gerontol., Ser. A, 54, B96
- Lichtenstein A. H., 1999, Nutr. Rev., 57, 14
- Jump D. B., 1999, Annu. Rev. Nutr., 19, 90
- Mangelsdorf D. J., 1995, Cell, 83, 850
- A, 1999, Cell, 97, 163
- Xu H. E., 1999, Mol. Cell, 3, 403
- Hu E., 1996, Science, 274, 2103
- Zhang B., 1996, J. Biol. Chem., 271, 31774
- Adams M., 1997, J. Biol. Chem., 272, 5132
- Camp H. S., 1999, Endocrinology, 140, 397
- Juge-Aubry C. E., 1999, J. Biol. Chem., 274, 10510
- McDonnell D. P., 1993, Bio/Technology, 11, 1261
- Lehmann J. M., 1995, J. Biol. Chem., 270, 12956
- Xu L., 1999, Curr. Opin. Genet. Dev., 9, 147
- Zhu Y., 1996, Gene Expression, 6, 195
- Dowell P., 1997, J. Biol. Chem., 272, 33443
- Zhu Y., 1997, J. Biol. Chem., 272, 25506
- Yuan C.-X., 1998, Proc. Natl. Acad. Sci. U.S.A., 95, 7944
- Treuter E., 1998, Mol. Endocrinol., 12, 881, 10.1210/mend.12.6.0123 · doi:10.1210/mend.12.6.0123 · Paper page
- Krey G., 1997, Mol. Endocrinol., 11, 791, 10.1210/mend.11.6.0007 · DOI · Paper page
- Zhou G., 1998, Mol. Endocrinol., 12, 1604, 10.1210/mend.12.10.0176 · doi:10.1210/mend.12.10.0176 · Paper page
- Berger J., 1996, Endocrinology, 137, 4195
- Young P. W., 1998, J. Pharmacol. Exp. Ther., 284, 759
- Bell A. R., 1998, Biochem. J., 332, 693
- Heuvel J. P. V, 1999, Toxicol. Sci., 47, 8
- Palmer C. N. A., 1998, Mol. Pharmacol., 53, 22
- Gervois P., 1999, Mol. Endocrinol., 13, 1549
- Gaw A., 1994, Handb. Exp. Pharmacol., 109, 348
- Brown P. J., 1997, Synthesis, 778, 782
- Brown P. J., 1999, J. Med. Chem., 42, 3788
- Forman B. M., 1997, Proc. Natl. Acad. Sci. U.S.A., 94, 4317
- Yu K., 1995, J. Biol. Chem., 270, 23983
- Palmer C. N. A., 1994, J. Biol. Chem., 269, 18089
- Lee S. S.-T., 1995, Mol. Cell. Biol., 15, 3022
- Peters J. M., 1997, J. Biol. Chem., 272, 27312
- Gaw A., 1999, Lipoproteins Health Dis., 1145, 1160
- Ross S. D., 1999, Arch. Intern. Med., 159, 1802
- Oliver M. F., 1984, Lancet, 2, 604
- Rutolo G., 1998, J. Am. Coll. Cardiol., 32, 1656
- Libby P., 1999, Mol. Basis Cardiovasc. Dis., 349, 366
- Spencer N. F. L., 1997, Int. Immunol., 9, 1588
- Delerive P., 1999, J. Biol. Chem., 45, 32054
- Vazquez M., 1995, Br. J. Pharmacol., 116, 2075
- Jacobsson A., 1985, J. Biol. Chem., 260, 16254
- Krook A., 1998, Diabetes, 47, 1531
- Ruyter B., 1997, Biochim. Biophys. Acta, 1348, 338
- Zhu Y., 1993, J. Biol. Chem., 268, 26820
- Greene M. E., 1995, Gene Expression, 4, 299
- Chawla A., 1994, Endocrinology, 135, 800, 10.1210/endo.135.2.8033830 · doi:10.1210/endo.135.2.8033830 · Paper page
- Saladin R., 1999, Cell Growth Differ., 10, 48
- Martin G., 1997, J. Biol. Chem., 272, 28217
- Hofmann C., 1994, Endocrinology, 134, 270, 10.1210/endo.134.1.8275942 · DOI · Paper page
- Tai T.-A. C., 1996, J. Biol. Chem., 271, 29914
- Kelly L. J., 1998, Endocrinology, 139, 4927
- Hulin B., 1996, Curr. Pharm. Des., 2, 102
- Kletzien R. F., 1992, Mol. Pharmacol., 41, 398
- Ibrahimi A., 1994, Mol. Pharmacol., 46, 1076
- Harris P. K. W., 1994, Mol. Pharmacol., 45, 445
- Willson T. M., 1996, J. Med. Chem., 39, 668
- Ide T., 1998, Diabetes Front, 9, 346
- Shinkai H., 1998, J. Med. Chem., 41, 1933
- Reginato M. J., 1998, J. Biol. Chem., 273, 32684
- Reddy K. A., 1999, J. Med. Chem., 42, 3278
- Sohda T., 1984, Chem. Pharm. Bull., 32, 4465
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2126
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2130
- Henke B. R., 1998, Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem
- Collins J. L., 1998, Structure−activity relationship and optimization of the phenyl alkyl ether moiety. J. Med. Chem
- Cobb J. E., 1998, N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists. 3. Structure−activity relationship and optimization of the N-aryl substituent. J. Med. Chem., 41, 5069
- Lehmann J. M., 1997, J. Biol. Chem., 272, 3410
- Verrando P., 1981, Biochim. Biophys. Acta, 663, 265
- Negishi M., 1995, J. Lipid Mediators Cell Signalling, 12, 448
- Narumiya S., 1991, Dev. Oncol., 67, 448
- Ikeda H., 1990, Arzneim.-Forsch., 40, 162
- Horikoshi H., 1994, Annu. Rep. Sankyo Res. Lab., 46, 57
- Prigeon R. L., 1998, J. Clin. Endocrinol. Metab., 83, 823
- Fonseca V. A., 1998, J. Clin. Endocrinol. Metab., 83, 3176
- Spencer C. M., 1997, Drugs, 54, 101
- Kumar S., 1996, Diabetologia, 39, 709
- Gimble J. M., 1996, Mol. Pharmacol., 50, 1094
- Jones S. A., 2000, Mol. Endocrinol., 14, 39, 10.1210/mend.14.1.0409 · doi:10.1210/mend.14.1.0409 · Paper page
- Blumberg B., 1998, Genes Dev., 12, 3205
- Ramachandran V., 1999, Drug Metab. Dispos., 27, 1199
- Yamazaki H., 1999, Drug Metab. Dispos., 27, 1266
- Pumford N. R., 1997, Annu. Rev. Pharmacol. Toxicol., 37, 117
- Miller V. A., 1997, J. Clin. Oncol., 15, 795
- Rizvi N. A., 1999, Clin. Cancer Res., 5, 1664
- Vidal-Puig A. J., 1997, J. Clin. Invest., 99, 2422
- Park K. S., 1997, Diabetes, 46, 1234
- Wu Z., 1998, J. Clin. Invest., 101, 32
- Sreenan S., 1999, Am. J. Physiol., 276, E1129
- Miles P. D. G., 1997, Diabetes, 46, 1683
- Yen C.-J., 1997, Biochem. Biophys. Res. Commun., 241, 274
- Deeb S. S., 1998, Nat. Genet., 20, 287
- Valve R., 1999, J. Clin. Endocrinol. Metab., 84, 3712
- Mori Y., 1998, Biochem. Biophys. Res. Commun., 251, 198
- Ek J., 1999, Diabetologia, 42, 895
- Hamann A., 1999, Eur. J. Endocrinol., 141, 92
- Girard J, 1997, Diabetes Metab., 23, 24
- McKeigue P., 1997, Handb. Hypertens., 17, 934
- Dubey R. K., 1993, Am. J. Physiol., 265, R732
- Zhang H. Y., 1994, Hypertension, 24, 110
- Morikang E., 1997, Am. J. Hypertens., 10, 446
- Law R. E., 1996, J. Clin. Invest., 98, 1905
- Kotchen T. A., 1996, Am. J. Physiol., 270, R666
- Zhang F., 1994, Hypertension, 24, 175
- Su C. G., 1999, J. Clin. Invest., 104, 389
- Ehrmann D. A., 1997, J. Clin. Endocrinol. Metab., 82, 2116
- Minamikawa J., 1998, J. Clin. Endocrinol. Metab., 83, 1820
- Suh N., 1999, Cancer Res., 59, 5673
- Lefebvre A.-M., 1998, Nat. Med., 4, 1057
- Schmidt A., 1992, Mol. Endocrinol., 6, 1641
- Amri E.-Z., 1995, J. Biol. Chem., 270, 2371
- Brooks C. D. W., 1996, J. Med. Chem., 39, 2654
- Brun R. P., 1996, Genes Dev., 10, 984
- Lim H., 1999, Genes Dev., 13, 1574
- He T.-C., 1999, Cell, 99, 345
- Cobb J., 1998, Annu. Rep. Med. Chem., 33, 222
- Sliskovic D. R., 1999, Annu. Rep. Med. Chem., 34, 110
- Belch J. J. F., 1998, Proc. Nutr. Soc., 57, 569
- Woutersen R. A., 1999, Mutat. Res., 443, 127
Cited by
Items 201–300 of 1,003
Seimandi, M., Lemaire, G., Pillon, A., Perrin, A., Carlavan, I., Voegel, J. J., Vignon, F., Nicolas, J., & Balaguer, P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.06.010 · Cited by 153
PPAR: a therapeutic target in Parkinson’s disease
Chaturvedi, R. K., & Beal, M. F. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05388.x · Cited by 146
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent
Artis, D. R., Lin, J. J., Zhang, C., Wang, W., Mehra, U., Perreault, M., Erbe, D., Krupka, H. I., England, B. P., Arnold, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811325106 · Cited by 148
D’Agostino, G., Russo, R., Avagliano, C., Cristiano, C., Meli, R., & Calignano, A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.25 · Cited by 164
Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present)
Takada, I., & Makishima, M. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1703952 · Cited by 155
Trifilieff, A., Bench, A., Hanley, M., Bayley, D., Campbell, E., & Whittaker, P. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705232 · Cited by 148
Li, Y., Pan, Y., Zhao, X., Wu, S., Li, F., Wang, Y.-X., Liu, B., Zhang, Y., Gao, X., Wang, Y., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.12.005 · Cited by 156
Place, A. E., Suh, N., Williams, C. R., Risingsong, R., Honda, T., Honda, Y., Gribble, G. W., Leesnitzer, L. M., Stimmel, J. B., Willson, T. M., et al. (2003) · PubMed · Cited by 149
Self-citationThe roles of PPARs in adipocyte differentiation
Grimaldi, P. A. (2001) · Progress in Lipid Research · doi:10.1016/s0163-7827(01)00005-4 · Cited by 163
SHIROSHITATAKESHITA, A., BRUNDEL, B., BURSTEIN, B., LEUNG, T., MITAMURA, H., OGAWA, S., & NATTEL, S. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.01.002 · Cited by 149
“We chose fenofibrate concentration based on concentrations in previous in vitro studies [26,27], which were comparable to concentrations achieved clinically [28].”
Metabolic Syndrome and Robustness Tradeoffs
Kitano, H., Oda, K., Kimura, T., Matsuoka, Y., Csete, M., Doyle, J., & Muramatsu, M. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s6 · Cited by 146
Gambino, R., Musso, G., & Cassader, M. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.3058 · Cited by 147
“Fibric acid derivatives available as lipid lowering agents serve as PPAR-a activators (326).”
Nuclear receptors as therapeutic targets in cholestatic liver diseases
Zollner, G., & Trauner, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00030.x · Cited by 146
“Bile acids reaching the systemic circulation are filtered at the glomerulus from plasma into urine thus establishing an alternative way for their excretion (Wilson et al., 1981).”
From Surface to Nuclear Receptors: The Endocannabinoid Family Extends its Assets
Pistis, M., & Melis, M. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790980014 · Cited by 142
“Clofibrate and fenofibrate activate PPAR- with a ten-fold selectivity over PPAR- , whereas bezafibrate displays similar potency at all three PPAR isoforms [83].”
BackgroundBarbier, O., Duran-Sandoval, D., Pineda-Torra, I., Kosykh, V., Fruchart, J.-C., & Staels, B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305361200 · Cited by 142
Su, X., Han, X., Mancuso, D. J., Abendschein, D. R., & Gross, R. W. (2005) · Biochemistry · doi:10.1021/bi047773a · Cited by 144
Heneka, M. T., Gavrilyuk, V., Landreth, G. E., O'Banion, M. K., Weinberg, G., & Feinstein, D. L. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01694.x · Cited by 142
Sivarajah, A., Chatterjee, P. K., Patel, N. S. A., Todorovic, Z., Hattori, Y., Brown, P. A. J., Stewart, K. N., Mota-Filipe, H., Cuzzocrea, S., & Thiemermann, C. (2003) · American Journal of Nephrology · doi:10.1159/000072088 · Cited by 146
Self-citationAltered PPARγ expression and activation after transient focal ischemia in rats
Victor, N. A., Wanderi, E. W., Gamboa, J., Zhao, X., Aronowski, J., Deininger, K., Lust, W. D., Landreth, G. E., & Sundararajan, S. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05037.x · Cited by 142
“Lipoprotein lipase (LPL) plays an important role in lipid metabolism; its promoter contains a PPRE and expression is increased by PPARc activation (Willson et al., 2000).”
BackgroundInfluentialDesign, synthesis and biological evaluation of nuclear receptor-degradation inducers
Itoh, Y., Kitaguchi, R., Ishikawa, M., Naito, M., & Hashimoto, Y. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.09.041 · Cited by 143
Sauerberg, P., Pettersson, I., Jeppesen, L., Bury, P. S., Mogensen, J. P., Wassermann, K., Brand, C. L., Sturis, J., Wöldike, H. F., Fleckner, J., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010964g · Cited by 142
Masamune, A., Kikuta, K., Satoh, M., Sakai, Y., Satoh, A., & Shimosegawa, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107582200 · Cited by 138
Rhodium-catalyzed oxidative C2-acylation of indoles with aryl and alkyl aldehydes
Zhou, B. N., Yang, Y., & Li, Y. (2012) · Chemical Communications · doi:10.1039/c2cc31351k · Cited by 141
Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists for the Treatment of Type 2 Diabetes
Henke, B. R. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030631e · Cited by 141
Self-citationArmstrong, E. H., Goswami, D., Griffin, P. R., Noy, N., & Ortlund, E. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.514646 · Cited by 133
“Because of the large number of target genes affected by this family of ligand-regulated transcription factors, LCFAs play a critical role in a variety of cellular processes and their related pathophysiologies, ranging from metabolic defects to cell differentiation and cancer progression (7, 8).”
BackgroundSuchanek, K. M., May, F. J., Robinson, J. A., Lee, W. J., Holman, N. A., Monteith, G. R., & Roberts‐Thomson, S. J. (2002) · Molecular Carcinogenesis · doi:10.1002/mc.10061 · Cited by 141
“A higher concentration of Wy-14,643 (100 mM) produced only slight increases in proliferation compared with controls; the selection of 10 mM Wy-14-643 for our studies appeared to be appropriate [26].”
BackgroundCheung, A. C., Lapointe‐Shaw, L., Kowgier, M., Meza‐Cardona, J., Hirschfield, G. M., Janssen, H. L. A., & Feld, J. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13465 · Cited by 139
“Bezafibrate activates all three isoforms of PPAR, while fenofibrate is effectively an isolated PPAR-a agonist.(14) Bezafibrate also has PPAR-independent effects that may mediate disease pathogenesis in PBC, and while these pathways are not fully understood, other nuclear receptors including the farsenoid-, pregnane- a…”
BackgroundPeroxisome proliferator-activated receptor-$gamma; ligands as cell-cycle modulators
Theocharis, S., Margeli, A. P., Vielh, P. R., & Kouraklis, G. P. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.04.004 · Cited by 139
Dasgupta, C., Sakurai, R., Wang, Y., Guo, P., Ambalavanan, N., Torday, J. S., & Rehan, V. K. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.90392.2008 · Cited by 137
Sertznig, P., Seifert, M., Tilgen, W., & Reichrath, J. (2008) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200809010-00002 · Cited by 150
Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARγ
Zander, T., Kraus, J. A., Grommes, C., Schlegel, U., Feinstein, D., Klockgether, T., Landreth, G., Koenigsknecht, J., & Heneka, M. T. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00899.x · Cited by 135
“PPARs belong to the nuclear hormone receptor super- family that are able to form heterodimers with the retinoic acid receptor thereby acting as ligand-activated transcription factors (Willson et al. 2000).”
BackgroundAhn, J. H., Shin, M. S., Jung, S. H., Kang, S. K., Kim, K. R., Rhee, S. D., Jung, W. H., Yang, S. D., Kim, S. J., Woo, J. R., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060389m · Cited by 141
Liver X Receptor Agonists as Potential Therapeutic Agents for Dyslipidemia and Atherosclerosis
Lund, E. G., Menke, J. G., & Sparrow, C. P. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000056743.42348.59 · Cited by 134
Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer.
Keith, R. L., Miller, Y. E., Hoshikawa, Y., Moore, M. D., Gesell, T., Gao, B., Malkinson, A. M., Golpon, H. A., Nemenoff, R. A., & Geraci, M. W. (2002) · PubMed · Cited by 142
Krämer, D. K., Al-Khalili, L., Perrini, S., Skogsberg, J., Wretenberg, P., Kannisto, K., Wallberg-Henriksson, H., Ehrenborg, E., Zierath, J. R., & Krook, A. (2005) · Diabetes · doi:10.2337/diabetes.54.4.1157 · Cited by 132
“PPAR and PPAR have been recognized as important regulators of lipid and carbohydrate metabolism and are targets for pharmacological compounds such as glitazones and fibrates, respectively (23).”
BackgroundMethodCOX‐2 and cancer: a new approach to an old problem
Bakhle, Y. S. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704365 · Cited by 149
“Each PPAR a ects a di erent range of genes, most of which are generally involved in lipid metabolism (Lowell, 1999; Clarke et al., 1999; Kersten et al., British Journal of Pharmacology vol 134 (6) 2000; Willson et al., 2000).”
BackgroundOrasanu, G., Ziouzenkova, O., Devchand, P. R., Nehra, V., Hamdy, O., Horton, E. S., & Plutzky, J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.055 · Cited by 143
“PPARs have a particularly large LBD, even as compared with other nuclear receptors ( 76 ).”
Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation
Belvisi, M. G., Hele, D. J., & Birrell, M. A. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.12.048 · Cited by 141
Ramanan, S., Kooshki, M., Zhao, W., Hsu, F.-C., Riddle, D. R., & Robbins, M. E. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.06.059 · Cited by 126
den Broeder, M. J., Kopylova, V. A., Kamminga, L. M., & Legler, J. (2015) · PPAR Research · doi:10.1155/2015/358029 · Cited by 137
“…(NSAIDs) [72] Fibrates (e.g., gemfibrozil, Bezafibrate, clofibrate, fenofibrate, ciprofibrate, pirinixic acid (Wy 14643), and GW2331) [3, 67, 73, 74] ETYA (5,8,11,14-eicosatetraynoic acid) ( Xenopus ) [66] PPARD Endogenous Fatty acids (e.g., docosahexaenoic acid, linoleic acid) [69] Very Low…”
Pharmacokinetic drug interactions in liver disease: An update
Palatini, P., & Martin, S. D. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i3.1260 · Cited by 142
Peroxisome proliferator-activated receptor γ in malignant diseases
WANG, T., Xu, J., Yu, X., Yang, R., & Han, Z. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.08.011 · Cited by 151
Barbier, O., Villeneuve, L., Bocher, V., Fontaine, C., Torra, I. P., Duhem, C., Kosykh, V., Fruchart, J.-C., Guillemette, C., & Staels, B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300749200 · Cited by 128
Lee, J. W., Bajwa, P. J., Carson, M. J., Jeske, D. R., Cong, Y., Elson, C. O., Lytle, C. Y., & Straus, D. S. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.113 · Cited by 135
Chawla, A., Sáez, E., & Evans, R. M. (2000) · Cell · doi:10.1016/s0092-8674(00)00097-0 · Cited by 133
Cardioprotective Effects of High-Density Lipoprotein Beyond its Anti-Atherogenic Action
Nagao, M., Nakajima, H., Toh, R., Hirata, K., & Ishida, T. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17025 · Cited by 133
Polak, P. E., Kalinin, S., Russo, C. D., Gavrilyuk, V., Sharp, A. J., Peters, J. M., Richardson, J. C., Willson, T. M., Weinberg, G. L., & Feinstein, D. L. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.07.006 · Cited by 138
“In response to ligand binding, PPARs undergo conformational changes leading to heterodimerization with the retinoic acid receptor (RXRa), binding to specific peroxisome proliferator response elements (PPREs) in promoter regions of target genes and modulation of transcriptional events (Willson et al., 2000).”
BackgroundSelf-citationSong, J., Knepper, M. A., Hu, X., Verbalis, J. G., & ECELBARGER, C. A. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.058008 · Cited by 127
“pose tissue, heart, large and small intestine, colon, and kidney (Willson et al., 2000).”
BackgroundInfluentialvan Doorn, M. B. A., Vogels, J., Tas, A. C., van Hoogdalem, E. J., Burggraaf, J., Cohen, A. F., & van der Greef, J. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02816.x · Cited by 134
X‐ray structure of the orphan nuclear receptor RORβ ligand‐binding domain in the active conformation
Stehlin, C., Wurtz, J., Steinmetz, A. C. U., Greiner, E. F., Schüle, R., Moras, D., & Renaud, J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.21.5822 · Cited by 133
Goetz, F. W., Rosauer, D. R., Sitar, S. P., Goetz, G., Simchick, C. A., Roberts, S., Johnson, R. B., Murphy, C. A., Bronte, C. R., & MacKenzie, S. A. (2010) · Molecular Ecology · doi:10.1111/j.1365-294x.2009.04481.x · Cited by 124
“PPARs are nuclear transcriptional factors that bind fatty acids and eicosanoids (Willson et al. 2000).”
BackgroundPPARs in the central nervous system: roles in neurodegeneration and neuroinflammation
Zolezzi, J. M., Santos, M. J., Bastías‐Candia, S., Pinto, C., Godoy, J. A., & Inestrosa, N. C. (2017) · Biological Reviews · doi:10.1111/brv.12320 · Cited by 122
“Biological Reviews 92 (2017) 2046–2069 © 2017 Cambridge Philosophical Society PPARs are part of the metabolic sub-family of nuclear receptors, which includes steroid, thyroid hormone, vitamin D and retinoid receptors (Willson et al., 2000).”
BackgroundHosonuma, K., Sato, K., Yamazaki, Y., Yanagisawa, M., Hashizume, H., Horiguchi, N., Kakizaki, S., Kusano, M., & Yamada, M. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.20 · Cited by 123
Ahmed, O. M., Abdel‐Moneim, A., Yazid, I. A., & Mahmoud, A. M. (2010) · Diabetologia Croatica · Cited by 189
Sierra, M. L., Bénéton, V., Boullay, A.-B., Boyer, T., Brewster, A. G., Donche, F., Forest, M.-C., Fouchet, M.-H., Gellibert, F. J., Grillot, D., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm058056x · Cited by 135
PPAR and Immune System-What Do We Know?
Zhang, X., & Young, H. A. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00057-7 · Cited by 123
Dang, Z., & Löwik, C. W. G. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040120 · Cited by 134
“Indeed, we observed that Wy14643 at 100 M and carbaprostacyclin at 10 M transactivated all isoforms of PPARs (data not shown), which is consistent with the observations in other cell lines.((26)) We and others have shown that activation of PPAR downregulated osteogenesis and upregulated adipogenesis.”
ResultAugustus, A., Yagyu, H., Haemmerle, G., Bensadoun, A., Vikramadithyan, R. K., Park, S.-Y., Kim, J. K., Zechner, R., & Goldberg, I. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401028200 · Cited by 121
Be different—The diversity of peroxisomes in the animal kingdom
Islinger, M., Cardoso, M. J., & Schrader, M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.03.013 · Cited by 136
Prospective de novo drug design with deep interactome learning
Atz, K., Cotos, L., Isert, C., Håkansson, M., Focht, D., Hilleke, M., Nippa, D. F., Iff, M., Ledergerber, J., Schiebroek, C. C. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47613-w · Cited by 127
“By balancing the importance of structural similarity, novelty, and other desired properties, we were able to guide the generation of molecules that met the desired criteria for the targeted application, such as PPARγ in this case.”
Yang, W., Rachez, C., & Freedman, L. P. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.21.8008-8017.2000 · Cited by 118
Naim, M. J., Alam, M. J., Ahmad, S., Nawaz, F., Shrivastava, N., Sahu, M., & Alam, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.02.031 · Cited by 120
Sertznig, P., Seifert, M., Tilgen, W., & Reichrath, J. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.20998 · Cited by 121
Westergaard, M., Henningsen, J., Rasmussen, S., Kristiansen, K., Johansen, C., Svendsen, M. L., Jensen, U. B., Schrøder, H. D., Staels, B., Iversen, L., et al. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12536.x · Cited by 128
Transcriptional Control of Apolipoprotein A-I Gene Expression in Diabetes
Mooradian, A. D., Haas, M. J., & Wong, N. C. W. (2004) · Diabetes · doi:10.2337/diabetes.53.3.513 · Cited by 119
Hydrogen/deuterium‐exchange (H/D‐Ex) of PPARγ LBD in the presence of various modulators
Hamuro, Y., Coales, S. J., Morrow, J. A., Molnar, K. S., Tuske, S. J., Southern, M. R., & Griffin, P. R. (2006) · Protein Science · doi:10.1110/ps.062103006 · Cited by 133
“PPARg plays a major role in the regulation of glucose and lipid homeostasis and is the molecular target for the antidiabetic agent rosiglitazone (Willson et al. 2000).”
BackgroundInfluentialTargeting PPAR receptors in the airway for the treatment of inflammatory lung disease
Belvisi, M. G., & Mitchell, J. A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00373.x · Cited by 127
“The essential fatty acids arachidonic acid, gamolenic acid, docosahexanoic acid and eicosapentaenoic acid, as well as modified oxidized lipids 9- and 13- hydroxyoctadecadienoic acid and 12- and 15- hydroxyeicosatetraenoic acid, bind to and activate PPARg (Willson et al., 2000).”
BackgroundInfluentialMcGuire, D. K., & Inzucchi, S. E. (2008) · Circulation · doi:10.1161/circulationaha.107.704080 · Cited by 122
Environmental chemical tributyltin augments adipocyte differentiation
Inadera, H., & Shimomura, A. (2005) · Toxicology Letters · doi:10.1016/j.toxlet.2005.05.015 · Cited by 125
Tachibana, K., Kobayashi, Y., Tanaka, T., Tagami, M., Sugiyama, A., Katayama, T., Ueda, C., Yamasaki, D., Ishimoto, K., Sumitomo, M., et al. (2005) · Nuclear Receptor · doi:10.1186/1478-1336-3-3 · Cited by 117
“Consistent with this relatively high divergence among the subtype-specific ligand binding domains, differential activation of PPARs by endogenous and exogenous compounds may account for the specific biological activity of the three PPAR subtypes [2,3].”
BackgroundGuo, L., & Tabrizchi, R. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.10.009 · Cited by 126
Ebdrup, S., Pettersson, I., Rasmussen, H. B., Deussen, H.-J., Jensen, A. F., Mortensen, S. B., Fleckner, J., Pridal, L., Nygaard, L., & Sauerberg, P. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021027r · Cited by 117
Li, Y., Qi, Y., Huang, T. H. W., Yamahara, J., & Roufogalis, B. D. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00708.x · Cited by 111
Palladium-catalyzed decarboxylative C2-acylation of indoles with α-oxocarboxylic acids
Pan, C., Jin, H., Liu, X., Cheng, Y., & Zhu, C. (2013) · Chemical Communications · doi:10.1039/c3cc40709h · Cited by 116
Boubia, B., Poupardin, O., Barth, M., Binet, J., Peralba, P., Mounier, L., Jacquier, E., Gauthier, E., Lepais, V., Chatar, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01285 · Cited by 110
Nugent, C., Prins, J. B., Whitehead, J. P., Wentworth, J. M., Chatterjee, V. K. K., & O'Rahilly, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009817200 · Cited by 122
DNA Binding-Independent Induction of I B Gene Transcription by PPAR
Delerive, P. (2002) · Molecular Endocrinology · doi:10.1210/me.16.5.1029 · Cited by 114
Peroxisome Proliferator-Activated Receptor α Reduces Cholesterol Esterification in Macrophages
Chinetti, G., Lestavel, S., Fruchart, J.-C., Clavey, V., & Staels, B. (2003) · Circulation Research · doi:10.1161/01.res.0000053386.46813.e9 · Cited by 113
Gandini, A., Bartolini, M., Tedesco, D., Martinez-Gonzalez, L., Roca, C., Campillo, N. E., Zaldivar-Diez, J., Perez, C., Zuccheri, G., Miti, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00610 · Cited by 107
Parsing the Role of PPARs in Macrophage Processes
Toobian, D., Ghosh, P., & Katkar, G. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.783780 · Cited by 120
Valasek, M. A., Clarke, S. L., & Repa, J. J. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700345-jlr200 · Cited by 112
“Peroxisome proliferator-activated receptor a (PPARa, NR1C1) is a member of the nuclear receptor superfamily and acts as a ligand-activated transcription factor in response to a variety of fatty acids (1, 2).”
BackgroundPpars, metabolic disease and atherosclerosis
Fruchart, J., Staels, B., & Duriez, P. (2001) · Pharmacological Research · doi:10.1006/phrs.2001.0871 · Cited by 129
Granlund, L., Juvet, L. K., Pedersen, J. I., & Nebb, H. I. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300120-jlr200 · Cited by 113
“The effects of these ligands are mediated by changes in the transcriptional rate of PPAR � target genes ( 11 ).”
BackgroundMarion‐Letellier, R., Butler, M., Déchelotte, P., Playford, R. J., & Ghosh, S. K. (2008) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.4.939 · Cited by 115
5-Arylidene-2,4-thiazolidinediones as inhibitors of protein tyrosine phosphatases
Maccari, R., Paoli, P., Ottanà, R., Jacomelli, M., Ciurleo, R., Manao, G., Steindl, T. M., Langer, T., Vigorita, M. G., & Camici, G. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.05.027 · Cited by 114
Iqbal, A. K. M., Khan, A. Y., Kalashetti, M. B., Belavagi, N. S., Gong, Y., & Khazi, I. A. M. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.04.015 · Cited by 113
Genetic interactions with diet influence the risk of cardiovascular disease
Ordovás, J. M. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.2.443s · Cited by 113
Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review
Palermo, A., D’Onofrio, L., Eastell, R., Schwartz, A. V., Pozzilli, P., & Napoli, N. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3123-0 · Cited by 114
“they change their structure and regulate gene transcription [55].”
BackgroundLi, S., Zhu, S., Xie, J., Song, S., Zhang, C., & Zhou, Q. (2010) · Journal of the American Chemical Society · doi:10.1021/ja909810k · Cited by 111
Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-140 · Cited by 107
“However, bezafibrate, in comparison with other fibrates has a unique characteristic profile of action since it activates all three PPAR subtypes (alpha, gamma and delta) at comparable doses [1-5].”
BackgroundYang, L., Guo, H., Li, Y., Meng, X., Lu, Y., Zhang, D., Wu, S., Zhou, H., Lu, P., Xie, Q., et al. (2016) · Scientific Reports · doi:10.1038/srep34611 · Cited by 122
Gupta, R. A., Polk, D. B., Krishna, U. S., Israel, D. A., Yan, F., DuBois, R. N., & Peek, R. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104141200 · Cited by 120
Dickey, A. S., Pineda, V. V., Tsunemi, T., Liu, P. P., Miranda, H. C., Gilmore-Hall, S. K., Lomas, N., Sampat, K. R., Buttgereit, A., Torres, M.-J. M., et al. (2015) · Nature Medicine · doi:10.1038/nm.4003 · Cited by 138
Teissier, E., Nohara, A., Chinetti, G., Paumelle, R., Cariou, B., Fruchart, J.-C., Brandes, R. P., Shah, A., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000150594.95988.45 · Cited by 110
Proline Oxidase, a Proapoptotic Gene, Is Induced by Troglitazone
Pandhare, J., Cooper, S. K., & Phang, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507867200 · Cited by 113
Meissner, M., Stein, M., Urbich, C., Reisinger, K., Suske, G., Staels, B., Kaufmann, R., & Gille, J. (2004) · Circulation Research · doi:10.1161/01.res.0000113781.08139.81 · Cited by 109
Coleman, J. D., Prabhu, K. S., Thompson, J. T., Reddy, P. S., Peters, J. M., Peterson, B. R., Reddy, C. C., & Heuvel, J. P. V. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.01.003 · Cited by 118
“Fatty acids and their metabolites are known endogenous agonists of all PPARs, with PPARβ/δ exhibiting similar structural and geometric preference as PPARα, whereas PPARγ tends to prefer longchain polyunsaturated fatty acids [26].”
BackgroundComparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
Rogue, A., Lambert, C., Jossé, R., Antherieu, S., Spire, C., Claude, N., & Guillouzo, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018816 · Cited by 105
Hong, G., Lockhart, A., Davis, B., Rahmoune, H., Baker, S., Ye, L., Thompson, P., Shou, Y., O'Shaughnessy, K., Ronco, P., et al. (2003) · The FASEB Journal · doi:10.1096/fj.03-0181fje · Cited by 110
“Electromobility shift assays were used to determine whether these putative PPREs bound PPARγ; these assays were performed in the presence of retinoic X receptor (RXR), with which PPARγ forms a heterodimer to constitute the DNA binding moiety (2).”
BackgroundMethodLjung, B., Bamberg, K., Dahllöf, B., Kjellstedt, A., Oakes, N. D., Östling, J., Svensson, L., & Camejo, G. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200127-jlr200 · Cited by 109
Metadata
- Authors
- Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R.
- Affiliations
- Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-02-01
- Volume
- 43
- Issue
- 4
- Pages
- 527-550
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1977666051
- Cited by
- 1,816
- References
- 216
- Citations by year
- 2026: 18 · 2025: 28 · 2024: 27 · 2023: 35 · 2022: 38 · 2021: 41 · 2020: 38 · 2019: 44 · 2018: 46 · 2017: 44 · 2016: 37 · 2015: 60 · 2014: 62 · 2013: 52 · 2012: 92
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- peroxisome proliferator-activated receptors, orphan receptors, drug discovery, receptor agonists, ligands, lipid signaling, nuclear receptors
- MeSH terms
- Animals, Diabetes Mellitus, Humans, Hyperlipidemias, Hypertension, Inflammation, Ligands, Models, Molecular, Neoplasms, Nuclear Proteins, Obesity, Transcription Factors, Drug Design, Receptors, Cytoplasmic and Nuclear
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.